<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations and diagnosis of irritable bowel syndrome in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations and diagnosis of irritable bowel syndrome in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations and diagnosis of irritable bowel syndrome in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold Wald, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nicholas J Talley, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 20, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Irritable bowel syndrome (IBS) is a functional disorder of the gastrointestinal tract characterized by chronic abdominal pain and altered bowel habits. However, only a small percentage of those affected seek medical attention [<a href="#rid1">1-5</a>]. Approximately 40 percent of individuals who meet diagnostic criteria for IBS do not have a formal diagnosis [<a href="#rid6">6</a>]. IBS is associated with increased health care costs and is the second highest cause of work absenteeism [<a href="#rid7">7,8</a>]. In the United States, IBS accounts for 25 to 50 percent of all referrals to gastroenterologists [<a href="#rid9">9</a>]. This topic will review the clinical manifestations and diagnosis of IBS. The pathophysiology and management of IBS are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2629.html" rel="external">"Pathophysiology of irritable bowel syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/2631.html" rel="external">"Treatment of irritable bowel syndrome in adults"</a>.)</p><p class="headingAnchor" id="H596144478"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H3941929805"><span class="h2">Prevalence</span><span class="headingEndMark"> — </span>The prevalence of irritable bowel syndrome (IBS) in North America estimated from population-based studies is approximately 10 to 15 percent [<a href="#rid1">1,2,10-14</a>]. In a meta-analysis that included eight international studies, the pooled prevalence of IBS was estimated to be 11 percent, with wide variation by geographic region [<a href="#rid15">15</a>]. The prevalence of IBS was 25 percent lower in those aged over 50 years as compared with those who were younger (OR, 0.75; 95% CI, 0.62-0.92) [<a href="#rid14">14</a>]. The overall prevalence of IBS in females was higher as compared with males (odds ratio 1.67 [95% CI 1.53–1.82]) [<a href="#rid16">16</a>]. This relative difference reflects an absolute difference in prevalence of approximately 5 percent between the sexes, with a prevalence in females and males of 14 and 9 percent, respectively. Females may be more likely to have constipation-predominant IBS as compared with males [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H3852197048"><span class="h2">Associated conditions</span><span class="headingEndMark"> — </span>IBS is associated with other conditions including fibromyalgia, chronic fatigue syndrome (also known as systemic exertion intolerance disease), gastroesophageal reflux disease, functional dyspepsia, non-cardiac chest pain, and psychiatric disorders including major depression, anxiety, and somatization [<a href="#rid17">17-21</a>]. (See  <a class="medical medical_review" href="/z/d/html/2629.html" rel="external">"Pathophysiology of irritable bowel syndrome", section on 'Psychosocial dysfunction'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Irritable bowel syndrome (IBS) is characterized by chronic abdominal pain and altered bowel habits [<a href="#rid17">17</a>]. </p><p class="headingAnchor" id="H3"><span class="h2">Chronic abdominal pain</span><span class="headingEndMark"> — </span>Abdominal pain in IBS is usually described as a cramping sensation with variable intensity and periodic exacerbations. The location and character of the pain can vary widely [<a href="#rid17">17,22</a>]. The severity of the pain may range from mild to severe. The pain is frequently related to defecation. While in some patients abdominal pain is relieved with defecation, some patients report worsening of pain with defecation [<a href="#rid23">23</a>]. Emotional stress and meals may exacerbate the pain. Patients with IBS also frequently report abdominal bloating and increased gas production in the form of flatulence or belching. </p><p class="headingAnchor" id="H4"><span class="h2">Altered bowel habits</span><span class="headingEndMark"> — </span>Symptoms of IBS include diarrhea, constipation, alternating diarrhea and constipation, or normal bowel habits alternating with either diarrhea and/or constipation.</p><p class="headingAnchor" id="H5"><span class="h3">Diarrhea</span><span class="headingEndMark"> — </span>Diarrhea is usually characterized as frequent loose stools of small to moderate volume. Bowel movements generally occur during waking hours, most often in the morning or after meals. Most bowel movements are preceded by lower abdominal cramping pain, urgency, and a sensation of incomplete evacuation or tenesmus. Approximately one-half of all patients with IBS complain of mucus discharge with stools [<a href="#rid24">24</a>]. Large volume diarrhea, bloody stools, nocturnal diarrhea, and greasy stools are not associated with IBS. </p><p class="headingAnchor" id="H6"><span class="h3">Constipation</span><span class="headingEndMark"> — </span>Stools are often hard and may be described as pellet-shaped. Patients may also experience tenesmus even when the rectum is empty. </p><p class="headingAnchor" id="H3717536218"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H3710510959"><span class="h2">Overview of diagnostic approach</span><span class="headingEndMark"> — </span>Irritable bowel syndrome (IBS) should be suspected in patients with chronic abdominal pain and altered bowel habits (constipation and/or diarrhea). A clinical diagnosis of IBS requires the fulfillment of symptom-based diagnostic criteria and a limited evaluation to exclude underlying organic disease [<a href="#rid25">25,26</a>]. (See <a class="local">'Diagnostic criteria'</a> below and <a class="local">'Initial evaluation'</a> below.)</p><p class="headingAnchor" id="H2263560866"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>In the absence of a biologic disease marker, several symptom-based criteria have been proposed to standardize the diagnosis of IBS. The most widely used among them are the Rome IV criteria.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rome IV criteria for IBS</strong> – According to the Rome IV criteria, IBS is defined as recurrent abdominal pain, on average, at least one day per week in the last three months, associated with two or more of the following criteria [<a href="#rid17">17,25</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Related to defecation</p><p class="bulletIndent2"><span class="glyph">•</span>Associated with a change in stool frequency</p><p class="bulletIndent2"><span class="glyph">•</span>Associated with a change in stool form (appearance) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IBS subtypes</strong> – Subtypes of IBS are recognized based on the patient's reported predominant bowel habit on days with abnormal bowel movements. The Bristol stool form scale (BSFS) should be used to record stool consistency [<a href="#rid27">27</a>]. Subtypes can only confidently be established when the patient is evaluated off medications used to treat bowel habit abnormalities. IBS subtypes are defined for clinical practice as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>IBS with predominant constipation</strong> – Patient reports that abnormal bowel movements are usually constipation (type 1 and 2 in the BSFS)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>IBS with predominant diarrhea</strong> – Patient reports that abnormal bowel movements are usually diarrhea (type 6 and 7 in the BSFS)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>IBS with mixed bowel habits</strong> – Patient reports that abnormal bowel movements are usually both constipation and diarrhea (more than one-fourth of all the abnormal bowel movements were constipation and more than one-fourth were diarrhea)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>IBS unclassified</strong> – Patients who meet diagnostic criteria for IBS but cannot be accurately categorized into one of the other three subtypes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other criteria</strong> – The Manning criteria include relief of pain with bowel movements, looser and more frequent stools with onset of pain, passage of mucus, and a sense of incomplete emptying  (<a class="graphic graphic_table graphicRef63034" href="/z/d/graphic/63034.html" rel="external">table 1</a>) [<a href="#rid24">24</a>]. There have been conflicting data regarding the predictive ability of the Manning criteria [<a href="#rid28">28-30</a>]. The Kruis criteria are less frequently used in clinical practice [<a href="#rid31">31,32</a>]. A number of studies have assessed the accuracy of the Rome and Manning criteria in a variety of practice settings [<a href="#rid33">33-36</a>]. As a result, some investigators continue to use the Manning criteria or a combination of both. No symptom-based criteria have ideal accuracy for diagnosing IBS; however, the Manning and Kruis criteria perform at least as well as the Rome I criteria [<a href="#rid10">10</a>].</p><p></p><p class="headingAnchor" id="H3598501161"><span class="h2">Initial evaluation</span></p><p class="headingAnchor" id="H1382979335"><span class="h3">History and physical examination</span><span class="headingEndMark"> — </span>The medical history serves to identify clinical manifestations of IBS as well as identify other possible causes of similar symptoms. The BSFS should be used to record stool consistency [<a href="#rid27">27</a>]. We perform a thorough history with particular attention to the symptoms that are concerning for organic disease. The history should include exposure to a variety of medications that can cause similar symptoms  (<a class="graphic graphic_table graphicRef71449" href="/z/d/graphic/71449.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef62307" href="/z/d/graphic/62307.html" rel="external">table 3</a>). A subgroup of patients report an acute viral or bacterial gastroenteritis prior to the onset of IBS symptoms. Family history assessment should include the presence of inflammatory bowel disease, colorectal cancer, and celiac disease. The physical examination is usually normal in patients with IBS. However, patients may have mild abdominal tenderness to palpation. In patients with constipation a rectal examination may be useful in identifying dyssynergic defecation [<a href="#rid37">37</a>]. (See <a class="local">'Additional evaluation based on the presence of alarm features'</a> below and  <a class="medical medical_review" href="/z/d/html/2637.html" rel="external">"Etiology and evaluation of chronic constipation in adults", section on 'History and physical examination'</a>.)</p><p class="headingAnchor" id="H2932381800"><span class="h3">Laboratory testing</span><span class="headingEndMark"> — </span>There is no definitive diagnostic laboratory test for IBS. The purpose of laboratory testing is primarily to exclude an alternative diagnosis. </p><p class="bulletIndent1"><span class="glyph">●</span>In all patients with suspected IBS, we perform a complete blood count. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with diarrhea, we perform the following [<a href="#rid26">26,38</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fecal calprotectin or fecal lactoferrin</p><p class="bulletIndent2"><span class="glyph">•</span>Stool testing for giardia (antigen detection or nucleic acid amplification assay) </p><p class="bulletIndent2"><span class="glyph">•</span>Serologic testing for celiac disease </p><p class="bulletIndent2"><span class="glyph">•</span>C-reactive protein levels, only if fecal calprotectin and fecal lactoferrin cannot be performed</p><p></p><p>A fecal calprotectin above a threshold level of 50 mcg/g had a pooled sensitivity and specificity for IBD of 81 and 87 percent, respectively [<a href="#rid26">26</a>]. Lactoferrin threshold values above the threshold range of 4.0 to 7.25 mg/g have a sensitivity and specificity for IBD of 79 and 93 percent, respectively. In a meta-analysis, patients with IBS symptoms and a CRP level of ≤0.5 or calprotectin level of ≤40μg/g, there was a ≤1 percent probability of IBD [<a href="#rid26">26,39</a>].</p><p>Data to support testing for celiac disease are conflicting. In a meta-analysis of 14 studies that included 4204 individuals, of whom 2278 (54 percent) met diagnostic criteria for IBS, 4 percent of patients had celiac disease [<a href="#rid40">40</a>]. However, almost all the studies included in this analysis were conducted outside the United States. A prospective multicenter study performed in the United States compared the prevalence of abnormal celiac antibodies and biopsy proven celiac disease in patients with non-constipated IBS to that of healthy controls. Although more than 7 percent of non-constipated IBS patients had celiac disease associated antibodies suggesting gluten sensitivity, the prevalence of biopsy proven celiac disease was similar to controls [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/4774.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4771.html" rel="external">"Diagnosis of celiac disease in adults", section on 'Serologic evaluation'</a>.)</p><p>The diagnostic role of antibodies to cytolethal distending toxin B (CdtB) and vinculin requires confirmation before they can be used in the evaluation of patients with suspected IBS [<a href="#rid42">42-44</a>]. One study that evaluated anti-CdtB and anti-vinculin titers in 2375 patients with IBS diarrhea, found that patients anti-CdtB were significantly<strong> </strong>higher in IBS diarrhea as compared to patients with IBD, healthy controls, celiac disease, and IBS constipation [<a href="#rid43">43</a>]. The specificity of anti-CdtB for IBS diarrhea was 92 percent but the sensitivity was only 44 percent. Anti-vinculin had a sensitivity and specificity of 33 and 84 percent, respectively.</p><p class="headingAnchor" id="H2525434223"><span class="h3">Other tests</span><span class="headingEndMark"> — </span>In addition, we perform a limited number of studies guided by the clinical presentation. These include the following: </p><p class="bulletIndent1"><span class="glyph">●</span>Age-appropriate colorectal cancer screening in all patients. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In IBS patients with constipation, abdominal radiograph to assess for stool accumulation and determine the severity. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We perform physiologic testing (anorectal manometry and balloon expulsion testing) to rule out dyssynergic defecation in patients with severe constipation that is refractory to management with dietary changes and osmotic laxative therapy. (See  <a class="medical medical_review" href="/z/d/html/2631.html" rel="external">"Treatment of irritable bowel syndrome in adults", section on 'Constipation'</a> and  <a class="medical medical_review" href="/z/d/html/2637.html" rel="external">"Etiology and evaluation of chronic constipation in adults", section on 'Defecation disorder'</a> and  <a class="medical medical_review" href="/z/d/html/2637.html" rel="external">"Etiology and evaluation of chronic constipation in adults", section on 'Assessment for a defecation disorder'</a> and  <a class="medical medical_review" href="/z/d/html/2637.html" rel="external">"Etiology and evaluation of chronic constipation in adults", section on 'Assessment of colonic transit'</a>.)</p><p></p><p class="headingAnchor" id="H3264629736"><span class="h2">Additional evaluation based on the presence of alarm features</span><span class="headingEndMark"> — </span>The extent of additional testing depends on the presence of alarm features. Although the presence of concerning features may identify patients more likely to have an organic disease, most patients will ultimately have a negative evaluation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alarm features</strong> – Alarm features include [<a href="#rid10">10</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age of onset after age 50 years</p><p class="bulletIndent2"><span class="glyph">•</span>Rectal bleeding or melena</p><p class="bulletIndent2"><span class="glyph">•</span>Nocturnal diarrhea</p><p class="bulletIndent2"><span class="glyph">•</span>Progressive abdominal pain</p><p class="bulletIndent2"><span class="glyph">•</span>Unexplained weight loss</p><p class="bulletIndent2"><span class="glyph">•</span>Laboratory abnormalities (iron deficiency anemia, elevated C-reactive protein or fecal calprotectin/lactoferrin)</p><p class="bulletIndent2"><span class="glyph">•</span>Family history of IBD or colorectal cancer</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients without alarm features</strong> – In patients who meet diagnostic criteria for IBS and have no alarm features, we do not routinely perform any additional testing beyond the initial evaluation. This limited diagnostic approach rules out organic disease in over 95 percent of patients [<a href="#rid45">45,46</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with alarm features </strong>– In patients with alarm features,<strong> </strong>we perform additional evaluation to exclude other causes of similar symptoms [<a href="#rid47">47</a>]. The diagnostic evaluation is based on the clinical presentation and usually includes endoscopic evaluation in all patients and imaging in selected cases. In patients with diarrhea, we perform colonoscopy to evaluate for the presence of IBD and perform biopsies to exclude microscopic colitis [<a href="#rid48">48-50</a>]. We reserve colonic imaging (eg, abdominal computed tomography scan) if there is a clinical suspicion for a structural lesion [<a href="#rid47">47</a>]. The imaging modality is guided by the clinical presentation. As an example, if pain, bloating, early satiety and constipation are of recent onset in a postmenopausal female, then we perform a pelvic imaging with an ultrasound and/or abdominal CT scan [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/z/d/html/2637.html" rel="external">"Etiology and evaluation of chronic constipation in adults", section on 'Endoscopy'</a> and  <a class="medical medical_review" href="/z/d/html/2606.html" rel="external">"Epidemiology and risk factors for colorectal cancer", section on 'Incidence'</a>.)</p><p></p><p class="headingAnchor" id="H898942585"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of irritable bowel syndrome (IBS) is broad. In patients with diarrhea-predominant symptoms, other important causes of chronic diarrhea include celiac disease, microscopic colitis, small intestinal bacterial overgrowth, and inflammatory bowel disease. Constipation may be secondary to organic disease, dyssynergic defecation, or slow colonic transit. While some of these alterative diagnoses are excluded during the course of evaluation in patients with suspected IBS, other diagnoses require additional diagnostic testing and need only be performed in selected patients with alarm features. Other causes of chronic diarrhea and constipation are discussed in detail separately. (See <a class="local">'Initial evaluation'</a> above and  <a class="medical medical_review" href="/z/d/html/2591.html" rel="external">"Approach to the adult with chronic diarrhea in resource-abundant settings"</a> and  <a class="medical medical_review" href="/z/d/html/2637.html" rel="external">"Etiology and evaluation of chronic constipation in adults"</a> and <a class="local">'Additional evaluation based on the presence of alarm features'</a> above.)</p><p class="headingAnchor" id="H3342103307"><span class="h1">DISEASE COURSE</span><span class="headingEndMark"> — </span>Most patients with irritable bowel syndrome (IBS) have chronic symptoms that vary in severity over time. In a systematic review that included clinic-based IBS patients with variable long term follow-up (six months to six years), 2 to 5 percent of patients were diagnosed with an alternate gastrointestinal disease. Symptoms remained unchanged or progressed in 30 to 50 percent and 2 to 18 percent, respectively [<a href="#rid52">52</a>]. An improvement in symptoms was reported in 12 to 38 percent of patients. Patients may also experience a change in IBS subtype over time with the most frequent change being from predominant constipation or diarrhea to mixed bowel habits.</p><p class="headingAnchor" id="H3303878023"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115088.html" rel="external">"Society guideline links: Irritable bowel syndrome"</a>.)</p><p class="headingAnchor" id="H1741294392"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15457.html" rel="external">"Patient education: Irritable bowel syndrome (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2014.html" rel="external">"Patient education: Irritable bowel syndrome (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/2000.html" rel="external">"Patient education: Chronic diarrhea in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology –</strong> Irritable bowel syndrome (IBS) is a functional disorder of the gastrointestinal tract characterized by chronic abdominal pain and altered bowel habits. The estimated prevalence of IBS globally is approximately 11 percent, with a higher prevalence in younger individuals and in females. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> <strong>–</strong> IBS is characterized by chronic abdominal pain and altered bowel habits. Abdominal pain in IBS is usually described as a cramping sensation with variable intensity and periodic exacerbations. The pain is frequently related to defecation. While in some patients abdominal pain is relieved with defecation, a substantial portion of patients report worsening of pain with defecation. Symptoms of IBS also include diarrhea, constipation, alternating diarrhea and constipation, or normal bowel habits alternating with either diarrhea and/or constipation. (See <a class="local">'Altered bowel habits'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease course</strong> <strong>–</strong> Most patients with IBS have chronic symptoms that vary in severity over time. Patients may also experience a change in IBS subtype over time with the most frequent change being from predominant constipation or diarrhea to mixed bowel habits. (See <a class="local">'Disease course'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> <strong>–</strong> IBS should be suspected in patients with chronic abdominal pain and altered bowel habits (constipation and/or diarrhea). A clinical diagnosis of IBS requires the fulfillment of symptom-based diagnostic criteria and a limited evaluation to exclude underlying organic disease. (See <a class="local">'Overview of diagnostic approach'</a> above.)</p><p></p><p class="bulletIndent1">According to the Rome IV criteria, IBS is defined as recurrent abdominal pain, on average, at least one day per week in the last three months, associated with two or more of the following criteria (see <a class="local">'Diagnostic criteria'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Related to defecation</p><p class="bulletIndent2"><span class="glyph">•</span>Associated with a change in stool frequency</p><p class="bulletIndent2"><span class="glyph">•</span>Associated with a change in stool form (appearance) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation</strong> <strong>–</strong> Initial evaluation in all patients with suspected IBS includes a history and physical examination and limited testing to evaluate for the presence of alarm features concerning for organic disease. (See <a class="local">'Initial evaluation'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In all patients with suspected IBS, we perform a complete blood count and age-appropriate colorectal cancer screening. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with diarrhea, we perform the following:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Fecal calprotectin or fecal lactoferrin</p><p class="bulletIndent3"><span class="glyph">-</span>Stool testing for giardia</p><p class="bulletIndent3"><span class="glyph">-</span>Serologic testing for celiac disease </p><p class="bulletIndent3"><span class="glyph">-</span>C-reactive protein levels only if fecal calprotectin and fecal lactoferrin cannot be performed</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alarm features concerning for underling organic disease – </strong>Alarm features include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age of onset after age 50 years</p><p class="bulletIndent2"><span class="glyph">•</span>Rectal bleeding or melena</p><p class="bulletIndent2"><span class="glyph">•</span>Nocturnal diarrhea</p><p class="bulletIndent2"><span class="glyph">•</span>Progressive abdominal pain</p><p class="bulletIndent2"><span class="glyph">•</span>Unexplained weight loss</p><p class="bulletIndent2"><span class="glyph">•</span>Laboratory abnormalities (eg, iron deficiency anemia, elevated C-reactive protein or fecal calprotectin/lactoferrin)</p><p class="bulletIndent2"><span class="glyph">•</span>Family history of inflammatory bowel disease or colorectal cancer</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional evaluation based on the presence of alarm features</strong>  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients who meet diagnostic criteria for IBS and have no alarm features, we do not routinely perform any additional testing beyond the initial evaluation. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with alarm features, we perform additional evaluation to exclude other causes of similar symptoms. The diagnostic evaluation is based on the clinical presentation and usually includes endoscopic evaluation in all patients and imaging in selected cases. (See <a class="local">'Additional evaluation based on the presence of alarm features'</a> above.)</p><p></p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ 3rd. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991; 101:927.</a></li><li><a class="nounderline abstract_t">Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38:1569.</a></li><li><a class="nounderline abstract_t">Jones R, Lydeard S. Irritable bowel syndrome in the general population. BMJ 1992; 304:87.</a></li><li><a class="nounderline abstract_t">Heaton KW, O'Donnell LJ, Braddon FE, et al. Symptoms of irritable bowel syndrome in a British urban community: consulters and nonconsulters. Gastroenterology 1992; 102:1962.</a></li><li><a class="nounderline abstract_t">Ford AC, Forman D, Bailey AG, et al. Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol 2008; 103:1229.</a></li><li><a class="nounderline abstract_t">Sayuk GS, Wolf R, Chang L. Comparison of Symptoms, Healthcare Utilization, and Treatment in Diagnosed and Undiagnosed Individuals With Diarrhea-Predominant Irritable Bowel Syndrome. Am J Gastroenterol 2017; 112:892.</a></li><li><a class="nounderline abstract_t">Schuster MM. Diagnostic evaluation of the irritable bowel syndrome. Gastroenterol Clin North Am 1991; 20:269.</a></li><li><a class="nounderline abstract_t">Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122:1500.</a></li><li><a class="nounderline abstract_t">Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 1991; 100:998.</a></li><li><a class="nounderline abstract_t">American College of Gastroenterology Task Force on Irritable Bowel Syndrome, Brandt LJ, Chey WD, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 Suppl 1:S1.</a></li><li><a class="nounderline abstract_t">Hahn BA, Saunders WB, Maier WC. Differences between individuals with self-reported irritable bowel syndrome (IBS) and IBS-like symptoms. Dig Dis Sci 1997; 42:2585.</a></li><li><a class="nounderline abstract_t">Saito YA, Locke GR, Talley NJ, et al. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol 2000; 95:2816.</a></li><li><a class="nounderline abstract_t">Thompson WG, Irvine EJ, Pare P, et al. Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci 2002; 47:225.</a></li><li><a class="nounderline abstract_t">Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10:712.</a></li><li><a class="nounderline abstract_t">Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003; 17:643.</a></li><li><a class="nounderline abstract_t">Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol 2012; 107:991.</a></li><li><a class="nounderline abstract_t">Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006; 130:1480.</a></li><li><a class="nounderline abstract_t">Lovell RM, Ford AC. Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis. Am J Gastroenterol 2012; 107:1793.</a></li><li><a class="nounderline abstract_t">Whorwell PJ, McCallum M, Creed FH, Roberts CT. Non-colonic features of irritable bowel syndrome. Gut 1986; 27:37.</a></li><li><a class="nounderline abstract_t">Hershfield NB. Nongastrointestinal symptoms of irritable bowel syndrome: an office-based clinical survey. Can J Gastroenterol 2005; 19:231.</a></li><li><a class="nounderline abstract_t">Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA 2015; 313:949.</a></li><li><a class="nounderline abstract_t">Swarbrick ET, Hegarty JE, Bat L, et al. Site of pain from the irritable bowel. Lancet 1980; 2:443.</a></li><li><a class="nounderline abstract_t">Simren M, Palsson OS, Whitehead WE. Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice. Curr Gastroenterol Rep 2017; 19:15.</a></li><li><a class="nounderline abstract_t">Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J 1978; 2:653.</a></li><li><a class="nounderline abstract_t">Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology 2016; 150:1393.</a></li><li><a class="nounderline abstract_t">Smalley W, Falck-Ytter C, Carrasco-Labra A, et al. AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D). Gastroenterology 2019; 157:851.</a></li><li><a class="nounderline abstract_t">Blake MR, Raker JM, Whelan K. Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2016; 44:693.</a></li><li><a class="nounderline abstract_t">Talley NJ, Phillips SF, Melton LJ, et al. Diagnostic value of the Manning criteria in irritable bowel syndrome. Gut 1990; 31:77.</a></li><li><a class="nounderline abstract_t">Smith RC, Greenbaum DS, Vancouver JB, et al. Gender differences in Manning criteria in the irritable bowel syndrome. Gastroenterology 1991; 100:591.</a></li><li><a class="nounderline abstract_t">Taub E, Cuevas JL, Cook EW 3rd, et al. Irritable bowel syndrome defined by factor analysis. Gender and race comparisons. Dig Dis Sci 1995; 40:2647.</a></li><li><a class="nounderline abstract_t">Kruis W, Thieme C, Weinzierl M, et al. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology 1984; 87:1.</a></li><li><a class="nounderline abstract_t">Frigerio G, Beretta A, Orsenigo G, et al. Irritable bowel syndrome. Still far from a positive diagnosis. Dig Dis Sci 1992; 37:164.</a></li><li><a class="nounderline abstract_t">Hammer J, Talley NJ. Diagnostic criteria for the irritable bowel syndrome. Am J Med 1999; 107:5S.</a></li><li><a class="nounderline abstract_t">Fass R, Longstreth GF, Pimentel M, et al. Evidence- and consensus-based practice guidelines for the diagnosis of irritable bowel syndrome. Arch Intern Med 2001; 161:2081.</a></li><li><a class="nounderline abstract_t">Vanner SJ, Depew WT, Paterson WG, et al. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol 1999; 94:2912.</a></li><li><a class="nounderline abstract_t">Ford AC, Bercik P, Morgan DG, et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology 2013; 145:1262.</a></li><li><a class="nounderline abstract_t">Talley NJ. How to do and interpret a rectal examination in gastroenterology. Am J Gastroenterol 2008; 103:820.</a></li><li><a class="nounderline abstract_t">Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol 2021; 116:17.</a></li><li><a class="nounderline abstract_t">Menees SB, Powell C, Kurlander J, et al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol 2015; 110:444.</a></li><li><a class="nounderline abstract_t">Ford AC, Chey WD, Talley NJ, et al. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med 2009; 169:651.</a></li><li><a class="nounderline abstract_t">Cash BD, Rubenstein JH, Young PE, et al. The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls. Gastroenterology 2011; 141:1187.</a></li><li><a class="nounderline abstract_t">Rezaie A, Park SC, Morales W, et al. Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome. Dig Dis Sci 2017; 62:1480.</a></li><li><a class="nounderline abstract_t">Pimentel M, Morales W, Rezaie A, et al. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects. PLoS One 2015; 10:e0126438.</a></li><li><a class="nounderline abstract_t">Schmulson M, Balbuena R, Corona de Law C. Clinical experience with the use of anti-CdtB and anti-vinculin antibodies in patients with diarrhea in Mexico. Rev Gastroenterol Mex 2016; 81:236.</a></li><li><a class="nounderline abstract_t">Schmulson MW, Chang L. Diagnostic approach to the patient with irritable bowel syndrome. Am J Med 1999; 107:20S.</a></li><li><a class="nounderline abstract_t">Svendsen JH, Munck LK, Andersen JR. Irritable bowel syndrome--prognosis and diagnostic safety. A 5-year follow-up study. Scand J Gastroenterol 1985; 20:415.</a></li><li><a class="nounderline abstract_t">O'Connor OJ, McSweeney SE, McWilliams S, et al. Role of radiologic imaging in irritable bowel syndrome: evidence-based review. Radiology 2012; 262:485.</a></li><li><a class="nounderline abstract_t">Guagnozzi D, Arias Á, Lucendo AJ. Systematic review with meta-analysis: diagnostic overlap of microscopic colitis and functional bowel disorders. Aliment Pharmacol Ther 2016; 43:851.</a></li><li><a class="nounderline abstract_t">Kamp EJ, Kane JS, Ford AC. Irritable Bowel Syndrome and Microscopic Colitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2016; 14:659.</a></li><li><a class="nounderline abstract_t">Gudsoorkar VS, Quigley EM. Distinguishing Microscopic Colitis From Irritable Bowel Syndrome. Clin Gastroenterol Hepatol 2016; 14:669.</a></li><li><a class="nounderline abstract_t">Goff B. Symptoms associated with ovarian cancer. Clin Obstet Gynecol 2012; 55:36.</a></li><li><a class="nounderline abstract_t">El-Serag HB, Pilgrim P, Schoenfeld P. Systemic review: Natural history of irritable bowel syndrome. Aliment Pharmacol Ther 2004; 19:861.</a></li></ol></div><div id="topicVersionRevision">Topic 2630 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1889716" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Epidemiology of colonic symptoms and the irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8359066" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1737146" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Irritable bowel syndrome in the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1587415" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Symptoms of irritable bowel syndrome in a British urban community: consulters and nonconsulters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18371141" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28094313" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Comparison of Symptoms, Healthcare Utilization, and Treatment in Diagnosed and Undiagnosed Individuals With Diarrhea-Predominant Irritable Bowel Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2066152" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Diagnostic evaluation of the irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11984534" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The burden of selected digestive diseases in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2001837" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Irritable bowel syndrome in office-based practice in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19521341" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : An evidence-based position statement on the management of irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9440642" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Differences between individuals with self-reported irritable bowel syndrome (IBS) and IBS-like symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11051354" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11837727" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22426087" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12641512" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22613905" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16678561" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Functional bowel disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23032982" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3949235" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Non-colonic features of irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15861265" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Nongastrointestinal symptoms of irritable bowel syndrome: an office-based clinical survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25734736" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Irritable bowel syndrome: a clinical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6106097" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Site of pain from the irritable bowel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28374308" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/698649" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Towards positive diagnosis of the irritable bowel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27144627" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Bowel Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31302098" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27492648" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2318433" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Diagnostic value of the Manning criteria in irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1993482" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Gender differences in Manning criteria in the irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8536526" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Irritable bowel syndrome defined by factor analysis. Gender and race comparisons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6724251" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1735330" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Irritable bowel syndrome. Still far from a positive diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10588167" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Diagnostic criteria for the irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11570936" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Evidence- and consensus-based practice guidelines for the diagnosis of irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10520844" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23994201" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18397419" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : How to do and interpret a rectal examination in gastroenterology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33315591" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : ACG Clinical Guideline: Management of Irritable Bowel Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25732419" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19364994" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21762658" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28451914" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25970536" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27681080" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Clinical experience with the use of anti-CdtB and anti-vinculin antibodies in patients with diarrhea in Mexico.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10588169" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Diagnostic approach to the patient with irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4023607" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Irritable bowel syndrome--prognosis and diagnostic safety. A 5-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22156992" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Role of radiologic imaging in irritable bowel syndrome: evidence-based review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26913568" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Systematic review with meta-analysis: diagnostic overlap of microscopic colitis and functional bowel disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26453949" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Irritable Bowel Syndrome and Microscopic Colitis: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26707680" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Distinguishing Microscopic Colitis From Irritable Bowel Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22343227" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Symptoms associated with ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15080847" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Systemic review: Natural history of irritable bowel syndrome.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
